Analysis of fluorescence in situ hybridization, mtDNA quantification, and mtDNA sequence for the detection of early bladder cancer

Cancer Genetics and Cytogenetics

Volumn 198, Issue 2, 2010, Pages 107-117

  Yoo, Jong Ha ^a,b   Suh, Borum ^b   Park, Tae Sung ^c   Shin, Myung Geun ^d   Choi, Yeung Deuk ^b   Lee, Chang Hoon ^e   Choi, Jong Rak ^b  

^a National Health Insurance Corporation   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Kyung Hee University Hospital   (South Korea)

^d Chonnam National University Medical School   (South Korea)

^e Konkuk University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

MITOCHONDRIAL DNA; NUCLEAR MATRIX PROTEIN 22;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER GRADING; CAPILLARY ELECTROPHORESIS; CONTROLLED STUDY; CYTOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DNA DETERMINATION; DNA SEQUENCE; EARLY CANCER; EPITHELIAL CELL URINE LEVEL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DOSAGE; GENE FREQUENCY; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMETHOD COMPARISON; MALE; MITOCHONDRIAL DNA DISORDER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; URINALYSIS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; DNA MUTATIONAL ANALYSIS; DNA, MITOCHONDRIAL; EARLY DETECTION OF CANCER; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; NUCLEAR PROTEINS; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 77950817607     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2009.12.017     Document Type: Article

References (64)

1. Tomera K.M. NMP22 BladderChek Test: point-of-care technology with life- and money-saving potential. Expert Rev Mol Diagn 2004, 4:783-794.
2. Black R.J., Bray F., Ferlay J., Parkin D.M. Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer 1997, 33:1075-1107.
3. Kim W.J., Kim W.J., Chung J.I., Chung J.I., Hong J.H., Hong J.H., Kim C.S., Kim C.S., Jung S.I., Jung S.I., Yoon D.K., Yoon D.K. Epidemiological study for urologic cancer in Korea (1998-2002). Korean J Urol 2004, 45:1081-1088.
4. Badalament R.A., Fair W.R., Whitmore W.F., Melamed M.R. The relative value of cytometry and cytology in the management of bladder cancer: the Memorial Sloan-Kettering Cancer Center experience. Semin Urol 1988, 6:22-30.
5. Grossman H.B., Soloway M., Messing E., Katz G., Stein B., Kassabian V., Shen Y. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA 2006, 295:299-305.
6. Kwon D.H., Kwon D.H., Hong S.J., Hong S.J. The Clinical Utility of BTA TRAK, BTA stat, NMP22 and urine cytology in the diagnosis of bladder cancer: a comparative study. Korean J Urol 2003, 44:721-726.
7. Park J.O., Park J.O., Moon D.G., Moon D.G., Cheon J., Cheon J., Kim J.J., Kim J.J., Yoon D.K. Urinary NMP (nuclear matrix protein) 22 in screening and post-treatment follow-up of bladder cancer. Korean J Urol 1999, 40:551-556.
8. Fitzgerald J.M., Ramchurren N., Rieger K., Levesque P., Silverman M., Libertino J.A., Summerhayes I.C. Identification of H-ras mutations in urine sediments complements cytology in the detection of bladder tumors. J Natl Cancer Inst 1995, 87:129-133.
9. Schmetter B.S., Habicht K.K., Lamm D.L., Morales A., Bander N.H., Grossman H.B., Hanna M.G., Silberman S.R., Butman B.T. A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer. J Urol 1997, 158:801-805.
10. Thomas L., Leyh H., Marberger M., Bombardieri E., Bassi P., Pagano F., Pansadoro V., Sternberg C.N., Boccon-Gibod L., Ravery V., Le Guludec D., Meulemans A., Conort P., Ishak L. Multicenter trial of the quantitative BTA TRAK assay in the detection of bladder cancer. Clin Chem 1999, 45:472-477.
11. Carpinito G.A., Stadler W.M., Briggman J.V., Chodak G.W., Church P.A., Lamm D.L., Lange P.H., Messing E.M., Pasciak R.M., Reservitz G.B., Ross R.N., Rukstalis D.B., Sarosdy M.F., Soloway M.S., Thiel R.P., Vogelzang N., Hayden C.L. Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract. J Urol 1996, 156:1280-1285.
12. Sarosdy M.F., Hudson M.A., Ellis W.J., Soloway M.S., deVere White R., Sheinfeld J., Jarowenko M.V., Schellhammer P.F., Schervish E.W., Patel J.V., Chodak G.W., Lamm D.L., Johnson R.D., Henderson M., Adams G., Blumenstein B.A., Thoelke K.R., Pfalzgraf R.D., Murchison H.A., Brunelle S.L. Improved detection of recurrent bladder cancer using the Bard BTA stat test. Urology 1997, 50:349-353.
13. Sarosdy M.F., Schellhammer P., Bokinsky G., Kahn P., Chao R., Yore L., Zadra J., Burzon D., Osher G., Bridge J.A., Anderson S., Johansson S.L., Lieber M., Soloway M., Flom K. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 2002, 168:1950-1954.
14. Fradet Y., Lockhard C. Performance characteristics of a new monoclonal antibody test for bladder cancer: ImmunoCyt trade mark. Can J Urol 1997, 4:400-405.
15. Lokeshwar V.B., Soloway M.S. Current bladder tumor tests: does their projected utility fulfill clinical necessity?. J Urol 2001, 165:1067-1077.
16. Van der Poel H.G., Van Balken M.R., Schamhart D.H., Peelen P., de Reijke T., Debruyne F.M., Schalken J.A., Witjes J.A. Bladder wash cytology, quantitative cytology, and the qualitative BTA test in patients with superficial bladder cancer. Urology 1998, 51:44-50.
17. Wiener H.G., Mian C., Haitel A., Pycha A., Schatzl G., Marberger M. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer?. J Urol 1998, 159:1876-1880.
18. Slaton J.W., Dinney C.P., Veltri R.W., Miller C.M., Liebert M., O'Dowd G.J., Grossman H.B. Deoxyribonucleic acid ploidy enhances the cytological prediction of recurrent transitional cell carcinoma of the bladder. J Urol 1997, 158:806-811.
19. Bubendorf L., Grilli B., Sauter G., Mihatsch M.J., Gasser T.C., Dalquen P. Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am J Clin Pathol 2001, 116:79-86.
20. Celep F., Karaguzel A., Ozgur G.K., Yildiz K. Detection of chromosomal aberrations in prostate cancer by fluorescence in situ hybridization (FISH). Eur Urol 2003, 44:666-671.
21. Kim M.H., Kim M.H., Choi E.H., Choi E.H., Kim J.H., Kim J.H., Kang S.Y., Kang S.Y., Chang S.G., Chang S.G., Yoo K.H., Yoo K.H., Suh J.T., Suh J.T., Lee W.I., Lee W.I. Clinical usefulness of fluorescence in situ hybridization for the detection of bladder cancer. Korean J Lab Med 2005, 25:199-204.
22. Mao L., Schoenberg M.P., Scicchitano M., Erozan Y.S., Merlo A., Schwab D., Sidransky D. Molecular detection of primary bladder cancer by microsatellite analysis. Science 1996, 271:659-662.
23. Halling K.C., King W., Sokolova I.A., Meyer R.G., Burkhardt H.M., Halling A.C., Cheville J.C., Sebo T.J., Ramakumar S., Stewart C.S., Pankratz S., O'Kane D.J., Seelig S.A., Lieber M.M., Jenkins R.B. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol 2000, 164:1768-1775.
24. Halling K.C., King W., Sokolova I.A., Karnes R.J., Meyer R.G., Powell E.L., Sebo T.J., Cheville J.C., Clayton A.C., Krajnik K.L., Ebert T.A., Nelson R.E., Burkhardt H.M., Ramakumar S., Stewart C.S., Pankratz V.S., Lieber M.M., Blute M.L., Zincke H., Seelig S.A., Jenkins R.B., O'Kane D.J. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. J Urol 2002, 167:2001-2006.
25. Skacel M., Fahmy M., Brainard J.A., Pettay J.D., Biscotti C.V., Liou L.S., Procop G.W., Jones J.S., Ulchaker J., Zippe C.D., Tubbs R.R. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol 2003, 169:2101-2105.
26. Orntoft T.F., Wolf H. Molecular alterations in bladder cancer. Urol Res 1998, 26:223-233.
27. Brandau S., Bhle A. Bladder cancer. I. Molecular and genetic basis of carcinogenesis. Eur Urol 2001, 39:491-497.
28. Pedersen P.L. Tumor mitochondria and the bioenergetics of cancer cells. Prog Exp Tumor Res 1978, 22:190-274.
29. Hoberman H.D. Is there a role for mitochondrial genes in carcinogenesis?. Cancer Res 1975, 35:3332-3335.
30. Anderson S., Bankier A.T., Barrell B.G., de Bruijn M.H., Coulson A.R., Drouin J., Eperon I.C., Nierlich D.P., Roe B.A., Sanger F., Schreier P.H., Smith A.J., Staden R., Young I.G. Sequence and organization of the human mitochondrial genome. Nature 1981, 290:457-465.
31. Allen J.A., Coombs M.M. Covalent binding of polycyclic aromatic compounds to mitochondrial and nuclear DNA. Nature 1980, 287:244-245.
32. Backer J.M., Weinstein I.B. Mitochondrial DNA is a major cellular target for a dihydrodiol-epoxide derivative of benzo[a]pyrene. Science 1980, 209:297-299.
33. Bhat N.K., Emeh J.K., Niranjan B.G., Avadhani N.G. Inhibition of mitochondrial protein synthesis during early stages of aflatoxin B1-induced hepatocarcinogenesis. Cancer Res 1982, 42:1876-1880.
34. Shigenaga M.K., Hagen T.M., Ames B.N. Oxidative damage and mitochondrial decay in aging. Proc Natl Acad Sci U S A 1994, 91:10771-10778.
35. Oberley L.W., Buettner G.R. Role of superoxide dismutase in cancer: a review. Cancer Res 1979, 39:1141-1149.
36. Clayton D.A., Doda J.N., Friedberg E.C. The absence of a pyrimidine dimer repair mechanism in mammalian mitochondria. Proc Natl Acad Sci U S A 1974, 71:2777-2781.
37. LeDoux S.P., Wilson G.L., Beecham E.J., Stevnsner T., Wassermann K., Bohr V.A. Repair of mitochondrial DNA after various types of DNA damage in Chinese hamster ovary cells. Carcinogenesis 1992, 13:1967-1973.
38. Croteau D.L., Bohr V.A. Repair of oxidative damage to nuclear and mitochondrial DNA in mammalian cells. J Biol Chem 1997, 272:25409-25412.
39. Kunkel T.A., Loeb L.A. Fidelity of mammalian DNA polymerases. Science 1981, 213:765-767.
40. Chen G.F., Chan F.L., Hong B.F., Chan L.W., Chan P.S. Mitochondrial DNA mutations in chemical carcinogen-induced rat bladder and human bladder cancer. Oncol Rep 2004, 12:463-472.
41. Penta J.S., Johnson F.M., Wachsman J.T., Copeland W.C. Mitochondrial DNA in human malignancy. Mutat Res 2001, 488:119-133.
42. Hibi K., Nakayama H., Yamazaki T., Takase T., Taguchi M., Kasai Y., Ito K., Akiyama S., Nakao A. Mitochondrial DNA alteration in esophageal cancer. Int J Cancer 2001, 92:319-321.
43. Wu C.W., Yin P.H., Hung W.Y., Li A.F., Li S.H., Chi C.W., Wei Y.H., Lee H.C. Mitochondrial DNA mutations and mitochondrial DNA depletion in gastric cancer. Genes Chromosomes Cancer 2005, 44:19-28.
44. Polyak K., Li Y., Zhu H., Lengauer C., Willson J.K., Markowitz S.D., Trush M.A., Kinzler K.W., Vogelstein B. Somatic mutations of the mitochondrial genome in human colorectal tumours. Nat Genet 1998, 20:291-293.
45. Tallini G., Ladanyi M., Rosai J., Jhanwar S.C. Analysis of nuclear and mitochondrial DNA alterations in thyroid and renal oncocytic tumors. Cytogenet Cell Genet 1994, 66:253-259.
46. Jeronimo C., Nomoto S., Caballero O.L., Usadel H., Henrique R., Varzim G., Oliveira J., Lopes C., Fliss M.S., Sidransky D. Mitochondrial mutations in early stage prostate cancer and bodily fluids. Oncogene 2001, 20:5195-5198.
47. Jiang W.W., Masayesva B., Zahurak M., Carvalho A.L., Rosenbaum E., Mambo E., Zhou S., Minhas K., Benoit N., Westra W.H., Alberg A., Sidransky D., Koch W., Califano J. Increased mitochondrial DNA content in saliva associated with head and neck cancer. Clin Cancer Res 2005, 11:2486-2491.
48. Jakupciak J.P., Maragh S., Markowitz M.E., Greenberg A.K., Hoque M.O., Maitra A., Barker P.E., Wagner P.D., Rom W.N., Srivastava S., Sidransky D., O'Connell C.D. Performance of mitochondrial DNA mutations detecting early stage cancer. BMC Cancer 2008, 8:285.
49. Barrientos A., Casademont J., Cardellach F., Estivill X., Urbano-Marquez A., Nunes V. Reduced steady-state levels of mitochondrial RNA and increased mitochondrial DNA amount in human brain with aging. Brain Res Mol Brain Res 1997, 52:284-289.
50. Mehra N., Penning M., Maas J., van Daal N., Giles R.H., Voest E.E. Circulating mitochondrial nucleic acids have prognostic value for survival in patients with advanced prostate cancer. Clin Cancer Res 2007, 13:421-426.
51. Sokolova I.A., Halling K.C., Jenkins R.B., Burkhardt H.M., Meyer R.G., Seelig S.A., King W. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn 2000, 2:116-123.
52. Cairns P., Shaw M.E., Knowles M.A. Initiation of bladder cancer may involve deletion of a tumour-suppressor gene on chromosome 9. Oncogene 1993, 8:1083-1085.
53. Spruck C.H., Ohneseit P.F., Gonzalez-Zulueta M., Esrig D., Miyao N., Tsai Y.C., Lerner S.P., Schmtte C., Yang A.S., Cote R. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994, 54:784-788.
54. Shin M.G., Levin B.C., Kim H.J., Kim H.R., Lee I.K., Cho D., Kee S.J., Shin J.H., Suh S.P., Ryang D.W. Profiling of length heteroplasmies in the human mitochondrial DNA control regions from blood cells in the Korean population. Electrophoresis 2006, 27:1331-1340.
55. Messing E.M., Young T.B., Hunt V.B., Gilchrist K.W., Newton M.A., Bram L.L., Hisgen W.J., Greenberg E.B., Kuglitsch M.E., Wegenke J.D. Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. Urology 1995, 45:387-396.
56. Stampfer D.S., Carpinito G.A., Rodriguez-Villanueva J., Willsey L.W., Dinney C.P., Grossman H.B., Fritsche H.A., McDougal W.S. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. J Urol 1998, 159:394-398.
57. Kapila K., Kehinde E.O., Anim J.T., Mojiminiyi O.A., Vinsu A., George S.S., Al-Maghrebi M., Al-Mulla F. Could nuclear matrix protein 22 (NMP22) play a role with urine cytology in screening for bladder cancer?-Experience at Kuwait University. Cytopathology 2008, 19:369-374.
58. Copeland W.C., Wachsman J.T., Johnson F.M., Penta J.S. Mitochondrial DNA alterations in cancer. Cancer Invest 2002, 20:557-569.
59. Wallace D.C. Mitochondrial diseases in man and mouse. Science 1999, 283:1482-1488.
60. Jazin E.E., Cavelier L., Eriksson I., Oreland L., Gyllensten U. Human brain contains high levels of heteroplasmy in the noncoding regions of mitochondrial DNA. Proc Natl Acad Sci U S A 1996, 93:12382-12387.
61. Chinnery P.F., Turnbull D.M. Mitochondrial DNA mutations in the pathogenesis of human disease. Mol Med Today 2000, 6:425-432.
62. Park S.Y., Shin M.G., Kim H.R., Oh J.Y., Kim S.H., Shin J.H., Cho Y.B., Suh S.P., Ryang D.W. Alteration of mitochondrial DNA sequence and copy number in nasal polyp tissue. Mitochondrion 2009, 9:318-325.
63. Lee H.C., Li S.H., Lin J.C., Wu C.C., Yeh D.C., Wei Y.H. Somatic mutations in the D-loop and decrease in the copy number of mitochondrial DNA in human hepatocellular carcinoma. Mutat Res 2004, 547:71-78.
64. Alexeyev M.F., Ledoux S.P., Wilson G.L. Mitochondrial DNA and aging. Clin Sci 2004, 107:355-364.